Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer

Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'

Piper Jaffray analyst Edward Tenthoff maintained an Underperform rating and $6 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA requested Sarepta provide additional dystrophin data from the ongoing confirmatory PROMOVI trial of eteplirsen. Sarepta plans to submit western blot data from biopsy... More

Jefferies Continues to See Low Probablity of Sarepta (SRPT) Approval

price target on Jefferies analyst Gena Wang maintained her Underperform rating and $7 PT on Sarepta Therapeutic (NASDAQ: SRPT), saying the dystrophin request is the best-case scenario, but they still see a slim chance of approval.

Wang commented, "We see FDA's request for additional... More

Wedbush Upgrades Sarepta Therapeutic (SRPT) to Outperform, $36 PT

Wedbush upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $36.00 (from $14.00), as FDA comes up with option 'C'.

Analyst Heather Behanna commented, "In our view, FDA has found middle ground and given Sarepta a rapid path towards accelerated... More

Sarepta (SPRT) volatility elevated into announcing FDA requesting more data up into FDA review of eteplirsen

Sarepta (NASDAQ: SRPT) is recently up $4.40 to $27.41 in the premarket after announcing that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its... More

Stocks with Implied Volatility Movement

Galena (NASDAQ: GALE) 209, EMC (NYSE: EMC) 28 implied volatility is above its IV index mean
LendingClub (NYSE: LC) 89, Seagate (NYSE: STX) 39 implied volatility is below its IV index... More

Sarepta (SPRT): FDA Request for Dystrophin Data a 'Clear Indication Willing to Grant Accelerated Approval' - Baird

Baird analyst Brian Skorney reiterated an Outperform rating and $23 price target on Sarepta Therapeutic (NASDAQ: SRPT), saying the FDA's request for dystrophin analysis is a positive for SRPT shares.

"We believe it signals a clear indication that the agency is willing to grant eteplirsen... More

Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - Leerink

Leerink affirms Sarepta (Nasdaq: SRPT) at Underperform with a price target of $5 after the company announced that the U.S. Food and Drug... More

After-Hours Stock Movers 06/06: (SRPT) (UNFI) (ZG) Higher; (DRYS) (MSTX) (ALXN) Lower (more...)

Today's After-Hours Movers:

Sarepta Therapeutics (NASDAQ: SRPT) 26.7% HIGHER; announced that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.

DryShips (NASDAQ:... More

Sarepta Therapeutics (SRPT) Surges as FDA Requests Dystrophin Data for eteplirsen NDA

Sarepta Therapeutics (NASDAQ: SRPT) is gaining sharply after the company announced that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing... More

Sarepta Therapeutics (SRPT) Says FDA Requests Dystrophin Data

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory... More